Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective Randomized Multi-center Study for Efficacy of Metallic Biliary Stent Compared to Plastic Stent in Patients Receiving Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04911647
Recruitment Status : Not yet recruiting
First Posted : June 3, 2021
Last Update Posted : June 3, 2021
Sponsor:
Information provided by (Responsible Party):
Yonsei University

Brief Summary:

Pancreatic cancer is the eighth most common occurrence in Korea. In the United States, pancreatic cancer is expected to be the number two cause of death from cancer in 2030. The prevalence of pancreatic cancer is also on the rise in Korea. The 5-year survival rate of pancreatic cancer in Korea is 10.8%. According to the 2017 cause of death statistics, pancreatic cancer mortality is ranked fifth. It is known to have the worst prognosis of cancer in the body. The median survival period of unresectable pancreatic cancer is only six months, and resection is the only treatment that can be expected to be completely cured, but only about 10% of cases are possible to be operable at the time of diagnosis.

In the 2000s, the studies began to emerge on diagnosis and treatment of pancreatic cancer with intermediate anatomical and imaging characteristics of resectable and locally advanced pancreatic cancer. Margin negative resection plays an important role in the long-term survival rate in surgical treatment of pancreatic cancer. Prior to 2001, pancreatic cancer with invasion of vein was considered impossible to perform radical resection. However, the studies have been published that a satisfactory long-term survival rate and margin negative resection could be obtained when venous resection was performed along with radical resection. Since the 2006, the National Comprehensive Cancer Network (NCCN) guideline, after performing radical resection among locally advanced pancreatic cancers without remote metastasis, pancreatic cancers with high risk of margin positive resection and treatment failure were classified as "borderline resectable". In the borderline resectable pancreatic cancer, neoadjuvant therapy was recommended before surgery. In recent years, the neoadjuvant therapy has been reported to raise the survival rate in resectable pancreatic cancer. Furthermore, a prospective study is in progress to demonstrate the effectiveness of neoadjuvant therapy with FOLFIRINOX in resectable pancreatic cancer. If pancreatic cancer is located in the head of pancreas, jaundice can be occurred often. In the case of preoperative jaundice, the possibility of postoperative complications increases. So biliary drainage is performed before surgery. In biliary drainage, usually the plastic stent was inserted through the endoscope. If the metal stent is inserted in the biliary obstruction, it can cause severe inflammation around the bile duct due to the radial force, and it is difficult to remove in the surgery. However, the meta-analysis comparing the groups of metal and plastic stents in the recent preoperative biliary drainage showed no difference of postoperative complication, and postoperative pancreatic fistula was lower in the group of metal stents (5.1% vs. 11.8% p=0.04). In addition, fewer re-intervention cases before surgery were found in the group of metal stents (3.4% vs.14.8% p < 0.0001).

Not only in the borderline resectable, but also in the resectable pancreatic cancer, neoadjuvant therapy has recently been actively performed in the cases of large tumor size, high CA 19-9, large lymph nodes, severe weight loss, and severe pain. The comparison study of the efficacy between plastic and metal stents in preoperative bile drainage in pancreatic cancer with neoadjuvant therapy has not yet been prospectively performed. However, retrospective studies have shown that metal stents have a lower re-treatment rate than plastic stent (0.24 vs 0.54), and that there is no difference in post-operative complications. Therefore, we planned the study to compare the efficacy and safety between metal and plastic stent in biliary drainage performed in patients undergoing neoadjuvant therapy with pancreatic cancer.


Condition or disease Intervention/treatment Phase
Resectable Pancreatic Cancer With Biliary Obstruction Device: ERCP using plastic stent Device: ERCP using metal stent Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 196 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Multi-center Study for Efficacy of Metallic Biliary Stent Compared to Plastic Stent in Patients Receiving Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Estimated Study Start Date : June 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: The Plastic stent
Patient group with plastic stent inserted in biliary obstruction through endoscope
Device: ERCP using plastic stent
Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.

Experimental: The metal stent
Patient group with metal stent inserted in biliary obstruction through endoscope
Device: ERCP using metal stent
Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.




Primary Outcome Measures :
  1. Re-intervention rate [ Time Frame: 6 months ]
    Re-intervention because of obstructive jaundice, cholangitis, stent malfunction, complication of procedure of ERCP


Secondary Outcome Measures :
  1. Procedure related complication, Postoperative complication [ Time Frame: 6 months ]
    1. Complication because of procedure (ERCP)
    2. Complication because of surgery



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients aged 20 years or older who have confirmed histologically or radiologically resectable pancreatic cancer
  2. Patients with clinical obstruction symptoms and radiographically confirmed biliary obstruction related to malignant tumors
  3. Patients receiving neoadjuvant chemotherapy before surgery

Exclusion Criteria:

  1. Patients diagnosed as unresectable pancreatic cancer
  2. Patients with biliary obstruction due to biliary cancer, not pancreatic cancer
  3. Patients with duodenal obstruction
  4. Patients with pancreatic cance and other cancers
  5. Patients with severe uncontrolled infection
  6. Patients with 3 or higher of performance score as the Eastern Cooperative Oncology Group
  7. Patients who have not agreed with the informed consent
  8. Patients who are technically unable to be undergone endoscopic procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04911647


Contacts
Layout table for location contacts
Contact: Seung Min Bang 82-2-2228-1995 bang7028@yuhs.ac

Locations
Layout table for location information
Korea, Republic of
Severance Hospital, Yonsei University Health System
Seoul, Korea, Republic of
Contact: Seung Min Bang    82-2-2228-1995    bang7028@yuhs.ac   
Sponsors and Collaborators
Yonsei University
Investigators
Layout table for investigator information
Principal Investigator: Seung Min Bang Severance Hospital, Yonsei University Health System
Layout table for additonal information
Responsible Party: Yonsei University
ClinicalTrials.gov Identifier: NCT04911647    
Other Study ID Numbers: 4-2021-0115
First Posted: June 3, 2021    Key Record Dates
Last Update Posted: June 3, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases